Novo Nordisk A/S (NYSE:NVO) Shares Bought by Verde Capital Management

Verde Capital Management lifted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 55.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 37,198 shares of the company's stock after acquiring an additional 13,294 shares during the quarter. Novo Nordisk A/S accounts for 0.7% of Verde Capital Management's investment portfolio, making the stock its 28th largest position. Verde Capital Management's holdings in Novo Nordisk A/S were worth $2,583,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. M. Kulyk & Associates LLC increased its position in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after acquiring an additional 119 shares during the period. Center for Financial Planning Inc. increased its stake in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the last quarter. Tradewinds Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 2.6% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after acquiring an additional 124 shares during the period. Exencial Wealth Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after acquiring an additional 124 shares during the period. Finally, Indie Asset Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock valued at $269,000 after acquiring an additional 126 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the subject of several recent research reports. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $128.00.

Novo Nordisk A/S Trading Up 2.8%

Shares of NYSE NVO traded up $1.94 during midday trading on Friday, hitting $71.40. The stock had a trading volume of 11,185,051 shares, compared to its average volume of 6,800,832. The company has a market capitalization of $320.41 billion, a price-to-earnings ratio of 21.70, a PEG ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a fifty day moving average price of $65.58 and a 200 day moving average price of $81.59.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.